Novel oral glucose lowering drugs cut risks in T2DM

February 8, 2017

(HealthDay)—For patients with type 2 diabetes, novel oral glucose lowering drugs (GLDs) are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, according to a study published online Jan. 24 in Diabetes, Obesity and Metabolism.

Thomas Nyström, M.D., from Karolinska Institutet in Stockholm, and colleagues compared use of novel oral GLDs (either dipeptidyl-peptidase-4 inhibitors [DPP-4i] or sodium glucose cotransporter-2 inhibitors) with in a propensity score matched analysis involving 21,758 patients matched in a 1:1 ratio.

The researchers observed reductions in the risk of all-cause , CVD, and hypoglycemia in the novel GLD group versus the group (hazard ratios [HRs], 0.56 [95 percent confidence interval (CI), 0.49 to 0.64], 0.85 [95 percent CI, 0.73 to 0.99], and 0.26 [95 percent CI, 0.12 to 0.57], respectively). Dapagliflozin correlated with lower risks of all-cause mortality and CVD (HRs, 0.44 [95 percent CI, 0.28 to 0.70] and 0.51 [95 percent CI, 0.30 to 0.86], respectively), while DPP-4i correlated with reduced risk of all-cause mortality (HR, 0.59 [95 percent CI, 0.51 to 0.67]) but not CVD (HR, 0.87 [95 percent CI, 0.75 to 1.01]).

"Dapagliflozin was associated with lower risk of both all-cause mortality and CVD, whereas DPP-4i was only associated with lower risk of all-cause mortality," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Diabetes requiring insulin tied to increased stroke risk in A-fib

More information: Full Text (subscription or payment may be required)

Related Stories

Diabetes requiring insulin tied to increased stroke risk in A-fib

January 26, 2017
(HealthDay)—For patients with atrial fibrillation (AF), diabetes requiring insulin, but not diabetes without insulin treatment, is associated with an increased risk of stroke/systemic embolism, according to a study published ...

Varying safety of add-on second-line T2DM treatments

June 17, 2016
(HealthDay)—For patients with type 2 diabetes who are taking metformin, the risk of cardiovascular events and mortality varies with the addition of different second-line therapies, according to a study published online ...

Lowest glucose variability for insulin + GLP-1 RA in T2DM

December 20, 2016
(HealthDay)—For patients with type 2 diabetes, the lowest glucose variability (GV) and hypoglycemia is seen for patients using basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), according to a study ...

Low blood glucose levels in hospitalized patients linked to increased mortality risk

November 17, 2016
In hospitalized patients, low blood sugar—also known as hypoglycemia—is associated with increased short- and long-term mortality risk, according to a new study published in the Endocrine Society's Journal of Clinical ...

Beta-blockers linked to reduced mortality in HFrEF, A-fib

January 12, 2017
(HealthDay)—β-blockers are associated with significantly reduced mortality, but not hospitalizations, in patients with heart failure and reduced ejection fraction (HFrEF) and atrial fibrillation (AF), according to a study ...

Insulin glargine 300 U/mL beats glargine 100 U/mL in T1DM

January 31, 2017
(HealthDay)—For patients with type 1 diabetes, receipt of insulin glargine 300 U/mL (Gla-300) is associated with better glucose control than glargine 100 U/mL (Gla-100), regardless of injection time, according to a study ...

Recommended for you

Smart mat detects early warning signs of foot ulcers

August 16, 2017
While completing his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s, Jon Bloom saw his fair share of foot amputations among patients with diabetes. The culprit: infected foot ulcers.

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

The best place to treat type 1 diabetes might be just under your skin

August 14, 2017
A group of U of T researchers have demonstrated that the space under our skin might be an optimal location to treat type 1 diabetes (T1D).

Injectable tissue patch could help repair damaged organs

August 14, 2017
A team of U of T Engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.

Air pollution linked to cardiovascular disease; air purifiers may lessen impact

August 14, 2017
Exposure to high levels of air pollution increased stress hormone levels and negative metabolic changes in otherwise healthy, young adults in a recent study conducted in China. Air purifiers appeared to lessen the negative ...

Study hints at experimental therapy for heart fibrosis

August 14, 2017
Researchers report encouraging preclinical results as they pursue elusive therapeutic strategies to repair scarred and poorly functioning heart tissues after cardiac injury—describing an experimental molecular treatment ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.